GlassScriptPhysician profile
Stacey Boudoin
NPI 1861459794
$4,070.02
in general payments reported to CMS, 2019-2025
24 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $495 · 2022: $548 · 2023: $797 · 2024: $1,140 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,026.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $882.50 | 2024-2025 | Xelstrym |
| Abbvie INC. | $620.36 | 2021-2025 | |
| Tris Pharma INC | $409.42 | 2021-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $402.40 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $282.22 | 2022-2025 | Caplyta |
| Corium, LLC | $278.12 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $272.95 | 2021-2025 | Trintellix |
| Lundbeck LLC | $189.61 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $126.63 | 2021-2025 | Rexulti |
| Alkermes, INC. | $86.26 | 2022-2023 | Lybalvi |
| Ironshore Pharmaceuticals INC. | $84.31 | 2022-2024 | |
| Axsome Therapeutics, INC. | $83.82 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $78.48 | 2025 | Fanapt |
| Neos Therapeutics, LP | $65.90 | 2021-2023 | Adzenys Xr-Odt |
| Jazz Pharmaceuticals INC. | $38.49 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $21.21 | 2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $21.11 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $19.33 | 2021 | |
| Neurocrine Biosciences, INC. | $19.33 | 2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $18.72 | 2023 | Spravato |
| Teva Pharmaceuticals USA, INC. | $18.46 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.79 | 2022 | |
| Eisai INC. | $17.30 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.30 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Boudoin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.